Raily Aesthetic Medicine International Expects 2024 Loss to Widen
Raily Aesthetic Medicine International Holdings (HKG:2135) expects a loss attributable to owners of 59 million yuan for 2024, compared with 32 million yuan in the prior year, according to a Monday filing with the Hong Kong bourse.
The company attributed the projected wider loss to impairments provisions in the business, increased share option expenses, and higher investment in research and development.
The company is expected to publish final results by the end of March.
The aesthetic medical services company stocks were down by 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available